Prosthetic Touch Signal Back to the Brain Hits a Glitch


Image Credit: Hector Picard/ Marie LaFauci


Restoring Touch Through Electrodes Implanted in the Human Brain will Require Engineering Around a Sensory Lag

 

More than 5 million people in the United States are affected by limb loss or paralysis. Technological devices that directly interact with the brain, known as brain-computer interfaces, offer the potential to decode an individual’s thoughts and translate them into action using a robotic arm or a cursor on a screen. These neuroprosthetics can take the place of an amputated or paralyzed arm, for instance, helping the user take an action.

Much research in this field to date has focused on decoding brain signals – what is it that the person wants to do?

But there’s another equally important part of any real-world prosthetic system. It needs to be able to convey information in the other direction, too, back to the brain to provide feedback from the external world. Think about how challenging it would be to interact with the world in the absence of touch. Tasks such as lighting a match, picking up an egg and grasping a coffee cup become tremendously difficult.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of David Caldwell Neurological Surgery Resident, University of California, San Francisco. Rajesh P. N. Rao Professor of Computer Science and Engineering and Director of the Center for Sensorimotor Neural Engineering, University of Washington.

 

At the University of Washington’s Center for Neurotechnology, our team is working out how best to engineer stimulation to the brain to restore tactile sensations that allow people to perform useful tasks. To this end, we are studying how people respond to sensation triggered by electrical stimulation of the brain. Our goal is to help devise a system that someday will allow someone who has lost the sense of touch to feel a loved one’s hand again.

Speed of Natural Touch Versus Brain Stimulation

To help localize the origin of a patient’s seizures prior to removing brain tissue to potentially help their epilepsy, Ojemann and Ko temporarily implant small, metal electrodes on top of and within the patient’s brain. These electrodes monitor the brain’s epileptic seizures so the neurosurgeons know where – and where not – to operate.

Our experiments use those same electrodes in two ways. We can record the electrical activity of the brain’s neurons. And we are also able to inject small amounts of electric current into specific parts of the brain. When we send a small burst of electricity to the touch-processing areas of the brain, the person experiences tactile sensations. In other words, when we activate particular neurons with electricity, the volunteer experiences it as if we were touching a particular part of their body.

In one study, we wanted to understand which tactile sensation an individual would perceive faster – artificial stimulation due to direct electrical stimulation of the brain via electrode, or natural tactile sensation due to a real touch on the patient’s hand?

We asked our subjects to press a button as quickly as possible using the hand opposite to where they felt the sensation. They were blindfolded to eliminate the potential for visual feedback that might confound our results.

 


Response times to direct stimulation of neurons in the brain were slower than response times to natural touch. Caldwell and Rao, CC BY-ND

 

What we discovered was surprising. Individuals responded more slowly to direct stimulation of their brain’s primary somatosensory cortex compared to a natural touch to their fingers. Even though an electric signal directly from the electrode in the brain bypassed all the peripheral nerves between the hand and head, the signal that traveled the longer journey up the ascending sensory nerves registered first.

This result held up even when we tested subjects again after a short break, suggesting that it cannot be explained solely as a novel sensation that the subjects needed time to learn.

Previous studies in nonhuman primates have found similar delays in reaction time relative to natural touch when researchers delivered electrical stimulation to a single location within somatosensory cortex. On the other hand, more recent research using multiple electrodes to stimulate somatosensory cortex in nonhuman primates found that such electrical stimulation could elicit response times slightly faster than natural touch.

Together, these studies demonstrate the complexities of stimulating the brain to replace natural tactile feedback. Future technologies and engineering strategies will need to take into account variability in touch sensation depending on how electrical stimulation is targeted in the brain.

 

Engineering Around a Sensory Lag

By discovering a delay in how people respond to direct electrical stimulation of their brains, we have revealed potential limitations in how current engineered solutions perform. The delay might limit how well future sensory neuroprosthetic devices using these clinical electrodes can work.

Fine motor movements – like picking up an egg without crushing it – rely on calibrating the effort based on what your sense of touch tells you.

Designers may need to account for a significant lag in artificial sensation relative to natural touch. For instance, if a user doesn’t receive feedback from touch sensors on a robotic hand quickly enough, and the overall system does not account for this delay in perception, someone attempting to pick up an egg with a robotic hand could apply too much pressure and crush it.

To improve reaction times and more broadly to enhance the utility of direct brain stimulation, we will need to take into account ongoing brain activity and tailor the electrical stimulation patterns for each person’s brain and the task at hand.

To achieve this goal, we have recently proposed a new type of brain-computer interface called a brain co-processor, which uses artificial intelligence to compute the best stimulation patterns for a task given current brain activity. Such an approach allows multiple electrodes to be used, possibly targeting multiple regions, and relies on co-adaptation with the brain to better approximate natural sensations.

Can electrical stimulation meaningfully substitute for natural touch during a complex task in the real world? We believe so. It will require both understanding the intricacies of information processing in the brain and incorporating this knowledge into future brain co-processors and neuroprosthetic devices for restoring touch.

 

Suggested Reading



Mapping Psilocybin’s Effect on the Brain



Therapeutic Research Advanced by Stem Cell Science





Is the Tesla-Bot (Optimus) Just a Fantasy?



Elon Musk Talks About Tesla Bots, Birth Rates, and Federal Incentives

 

Stay up to date. Follow us:

 

NeuroOne Medical Technologies (NMTC) Scheduled to Present at NobleCon18 Investor Conference


NeuroOne CEO David Rosa provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on NMTC


NobleCon18 Presenting Companies

About NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .

BioSig Technologies (BSGM) Scheduled to Present at NobleCon18 Investor Conference


BioSig Technologies CEO Kenneth Londoner provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on BSGM


NobleCon18 Presenting Companies

About BioSig

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Genprex (GNPX) Scheduled to Present at NobleCon18 Investor Conference


Genprex CFO Ryan Confer provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on GNPX


NobleCon18 Presenting Companies

About Genprex

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda

Healthcare Triangle (HCTI) Scheduled to Present at NobleCon18 Investor Conference


Healthcare Triangle CEO Suresh Venkatachari provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on HCTI


NobleCon18 Presenting Companies

About Healthcare Triangle

Healthcare Triangle is a leading healthcare information technology company focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the healthcare and life sciences industry. Healthcare Triangle is an AWS Partner.

GABY Inc. (GABLF) – GABY Inc.: Focused on California Cannabis Consolidation

Monday, April 04, 2022

GABY Inc. (GABLF)
GABY Inc.: Focused on California Cannabis Consolidation

Gaby Inc is a wellness company that is engaged in the marketing of a variety of cannabis products, including flowers, concentrates, pre-rolls, edibles, topicals, tinctures, and other products. Some of its brands are Mankind, Sonoma Pacific, 2Rise, Lulu’s, and the Kind Republic. The company operates in two segments, namely licensed and unlicensed channels, both of which are in the manufacturing, distribution, and marketing of wellness products to address a variety of dietary and health concerns. All of its revenue comes from the United States.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage. We are initiating research coverage on GABY Inc. GABY Inc. is a California-focused cannabis retail consolidator and the owner of San Diego-based Mankind Dispensary, one of the oldest and largest licensed dispensaries in the state. With significant organic and inorganic growth opportunities, we believe GABLF shares present an attractive risk/reward situation.

    Focus on California Consolidation.  GABY’s overarching strategy is to consolidate dispensaries in California. The Company’s first step was the April 2021 acquisition of Mankind Dispensary. The California market remains highly fragmented. No brand owns more than 2.5% of the retail dispensary locations and 4% of overall market share. Ripe for consolidation, in our view …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

BioSig Technologies (BSGM) – Q4 2021 Misses But Pieces Are Falling In Place

Friday, April 01, 2022

BioSig Technologies (BSGM)
Q4 2021 Misses But Pieces Are Falling In Place

BioSig Technologies, Inc. is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. PURE EP is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP System has received FDA 510(k) clearance and installed its first commercial sale in February 2021. The company looks to apply their unique bioelectronic technology across additional disease conditions, including nervous system disorders, auto-immune diseases, hypertension, and pain.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q4 2021 reported. Yesterday, BioSig Technologies reported their fourth quarter, missing on top-line expectations, with no unit sales reported. That said, the company continues to roll out a phased commercialization strategy to promote faster revenue growth longer term.

    Recent hires are expected to move the needle.  In December 2021, the company introduced Gray Fleming as Chief Commercial Officer and acquired the services of Access Strategy Partners to assist in relationship management. Just last week, the company introduced John Sieckhaus as Chief Operating Officer. All these filled positions are upgrades or new positions that are expected to produce better …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

PDS Biotechnology Corp (PDSB) – FY2021 Reported With Clinical Trial Progress

Friday, April 01, 2022

PDS Biotechnology Corp (PDSB)
FY2021 Reported With Clinical Trial Progress

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    FY2021 Results Were Within Expectations.  PDS Biotech reported 4Q21 loss of $6.3 million or $(0.23) per share, bringing the FY2021 loss to $16.9 million or $(0.66) per share. On its quarterly conference call, the company discussed pipeline developments in several HPV-positive cancer trials, preclinical products, and its infectious disease platform. Cash at December 31, 2021 was $65.2 million.

    PDS0101 Has Recently Achieved Important Milestones.  The VERSATILE-002 trial is testing PDS0101 in combination with Keytruda (pembrolizumab), the PD-1 checkpoint inhibitor. The company has recently presented safety data, announced a preliminary efficacy milestone that allows the trial to continue to completion, and continues to enroll patients …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

How Big is the News in the Telomere-to-Telomere Reports


Image Source: nih.gov


Human Genome Gaps in Understanding are Now Filled by Six New Reports

 

When it was announced in 2003 that the human genome had been mapped, the accomplishment was and continues to be life-changing for the species. But the mapping wasn’t fully complete. While it opened doors to understanding and continues to open doors to medical breakthroughs, it was only 92% complete. That is no longer the case. Yesterday (March 31), the official reports on the first end-to-end human genome map was published.

Now that scientists have a complete map with no significant gaps, the enhanced knowledge will no doubt lead to filling in evolutionary questions while providing insights into birth defects, auto-immune problems, cancer, and aging. The six separate papers just published include parts of the genome that were left uncharacterized because of available DNA sequencing technology two decades ago. After 20 years, these limits have been overcome. This is again momentous for the species as it will lead to discoveries and techniques that will only be realized over time.

While filling gaps in understanding and discovering 99 more new genes believed to code for proteins, the scientists also corrected thousands of errors in an earlier map of human DNA. This map from 2003 has been serving those in the field, including researchers, geneticists, and medical doctors. The original $3 billion Human Genome Project sought to unveil the purpose of every letter of a human’s DNA, but even with refinements made after the original conclusions, it is believed to have found only about 92% of them.

 

Exploiting the new map for medical care or evolution discovery provides another exciting start with new information to assess when figuring out diseases that are known to be inherited, but uncertainty exists as to where the faulty gene resides.

The new map cost a few million dollars to create, according to Adam Phillippy, a computational biologist at the National Human Genome Research Institute. This reflects how technology and understanding have brought down gene sequencing costs.

The twin strands of DNA in human cells contain about three billion letter pairs spread among 23 pairs of chromosomes. The genetic material helps determine eye and hair color, stature, and other physical characteristics, as well as risks for certain diseases. Scientists liken sequencing to solving a jigsaw puzzle, they look at a few segments and try to find what fits. Since there are two strands (one contributed by the mother, the other by the father) they used their computers to focus on only one puzzle, paternal DNA.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Ultra-Rapid DNA Sequencing Identifies Rare Diseases in Hours



Pros and Cons of FDA Funded in Part by Companies





Cells that Can be Produced from Stem Cells



Stem-Cell Based Therapy for Alzheimer’s Disease

 

Sources

https://www.science.org/doi/10.1126/science.abj6987

https://www.genome.gov/about-genomics/telomere-to-telomere

https://www.wsj.com/articles/first-gapless-human-genome-map-is-unveiled-years-after-earlier-effort-11648750303

https://theconversation.com/us/technology

https://www.genome.gov/

 

Stay up to date. Follow us:

 

How Big is the News in the Telomere-to-Telomere Reports?


Image Source: nih.gov


Human Genome Gaps in Understanding are Now Filled by Six New Reports

 

When it was announced in 2003 that the human genome had been mapped, the accomplishment was and continues to be life-changing for the species. But the mapping wasn’t fully complete. While it opened doors to understanding and continues to open doors to medical breakthroughs, it was only 92% complete. That is no longer the case. Yesterday (March 31), the official reports on the first end-to-end human genome map was published.

Now that scientists have a complete map with no significant gaps, the enhanced knowledge will no doubt lead to filling in evolutionary questions while providing insights into birth defects, auto-immune problems, cancer, and aging. The six separate papers just published include parts of the genome that were left uncharacterized because of available DNA sequencing technology two decades ago. After 20 years, these limits have been overcome. This is again momentous for the species as it will lead to discoveries and techniques that will only be realized over time.

While filling gaps in understanding and discovering 99 more new genes believed to code for proteins, the scientists also corrected thousands of errors in an earlier map of human DNA. This map from 2003 has been serving those in the field, including researchers, geneticists, and medical doctors. The original $3 billion Human Genome Project sought to unveil the purpose of every letter of a human’s DNA, but even with refinements made after the original conclusions, it is believed to have found only about 92% of them.

 

Exploiting the new map for medical care or evolution discovery provides another exciting start with new information to assess when figuring out diseases that are known to be inherited, but uncertainty exists as to where the faulty gene resides.

The new map cost a few million dollars to create, according to Adam Phillippy, a computational biologist at the National Human Genome Research Institute. This reflects how technology and understanding have brought down gene sequencing costs.

The twin strands of DNA in human cells contain about three billion letter pairs spread among 23 pairs of chromosomes. The genetic material helps determine eye and hair color, stature, and other physical characteristics, as well as risks for certain diseases. Scientists liken sequencing to solving a jigsaw puzzle, they look at a few segments and try to find what fits. Since there are two strands (one contributed by the mother, the other by the father) they used their computers to focus on only one puzzle, paternal DNA.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Ultra-Rapid DNA Sequencing Identifies Rare Diseases in Hours



Pros and Cons of FDA Funded in Part by Companies





Cells that Can be Produced from Stem Cells



Stem-Cell Based Therapy for Alzheimer’s Disease

 

Sources

https://www.science.org/doi/10.1126/science.abj6987

https://www.genome.gov/about-genomics/telomere-to-telomere

https://www.wsj.com/articles/first-gapless-human-genome-map-is-unveiled-years-after-earlier-effort-11648750303

https://theconversation.com/us/technology

https://www.genome.gov/

 

Stay up to date. Follow us:

 

Avivagen Inc. (VIVXF)(VIV:CA) – Reports First Quarter 2022 Results

Thursday, March 31, 2022

Avivagen Inc. (VIVXF)(VIV:CA)
Reports First Quarter 2022 Results

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    1Q22 Results. Avivagen reported revenue of $271,157 (all figures in Canadian $) in the quarter, up from $261,987 last year, and compared to our $300,000 estimate. Net loss for the quarter was $1.6 million, or $0.03 per share versus a net loss of $1.3 million, or $0.03 per share, in the first quarter of 2021. We had forecasted a net loss of $1.4 million, or $0.03 per share. Increased operating expenses due to impairment expenses were the main driver in the increased loss.

    Market Still Challenging.  While sales in the Philippines continue apace, Mexico remains frozen. In fact, quarterly revenues were reduced by $89,658 due to returned product from Mexico. Average price per kg of OxC-Beta remained flat at $106.33. While Avivagen has made strides in receiving approvals in other nations, the Company needs to translate approvals into steady, and increasing, sales in more …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Axcella Therapeutics (AXLA) – Axcella Reports FY2021 With Clinical Data Expected In 2H22

Thursday, March 31, 2022

Axcella Therapeutics (AXLA)
Axcella Reports FY2021 With Clinical Data Expected In 2H22

Axcella Health Inc. is a clinical-stage biotechnology company focused on treating complex diseases and improvinge health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company’s pipeline includes two lead therapeutic candidates:, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy (OHE) , and AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH).

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Financial Results Reported for 4Q and FY2021.  Axcella Reported a 4Q21 loss of $17.9 million or $(0.46) per share, bringing the full year loss to $64.6 million or $(1.70) per share. Clinical trial enrollment is progressing as expected, with data announcements expected in 2H22. The company reported cash of $55.0 million on December 31, excluding the registered direct offering of $25.0 million completed in March 2022.

    Long COVID Phase 2a Trial Has Begun Axcella has begun enrolling patients in a Phase 2a trial designed to test AXA1125 on Long COVID symptoms of fatigue and muscle weakness.  This double-blind placebo-controlled trial treats patients with either AXA1125 or placebo for 28 days. It has a target enrollment of 40 patients, with endpoints including measures of muscle recovery time after exertion …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Wesana Health (WSNAF) Scheduled to Present at NobleCon18 Investor Conference


Wesana Health CEO Daniel Carcillo provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on WSNAF


NobleCon18 Presenting Companies

About Wesana

Wesana Health?helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at?www.wesanahealth.com.